Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers von Hutchinson, Katherine E, Chen, Jessica W, Savage, Heidi M, Stout, Thomas J, Schimmoller, Frauke, Cortés, Javier, Dent, Susan, Harbeck, Nadia, Jacot, William, Krop, Ian, Trabucco, Sally E, Sivakumar, Smruthy, Sokol, Ethan S, Wilson, Timothy R

Volltext

ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes von Chen, Jessica W, Jacot, William, Cortés, Javier, Krop, Ian E, Dent, Susan, Harbeck, Nadia, De Laurentiis, Michelino, Diéras, Véronique, Im, Young-Hyuck, Stout, Thomas J, Schimmoller, Frauke, Savage, Heidi M, Hutchinson, Katherine E, Wilson, Timothy R

Volltext

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy von Ignatiadis, Michail, Van den Eynden, Gert, Roberto, Salgado, Fornili, Marco, Bareche, Yacine, Desmedt, Christine, Rothé, Françoise, Maetens, Marion, Venet, David, Holgado, Esther, McNally, Virginia, Kiermaier, Astrid, Savage, Heidi M, Wilson, Timothy R, Cortes, Javier, Schneeweiss, Andreas, Willard-Gallo, Karen, Biganzoli, Elia, Sotiriou, Christos

Volltext

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors von Juric, Dejan, Krop, Ian, Ramanathan, Ramesh K, Wilson, Timothy R, Ware, Joseph A, Sanabria Bohorquez, Sandra M, Savage, Heidi M, Sampath, Deepak, Salphati, Laurent, Lin, Ray S, Jin, Huan, Parmar, Hema, Hsu, Jerry Y, Von Hoff, Daniel D, Baselga, José

Volltext

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers von Jhaveri, Komal, Chang, Matthew T., Juric, Dejan, Saura, Cristina, Gambardella, Valentina, Melnyk, Anton, Patel, Manish R., Ribrag, Vincent, Ma, Cynthia X., Aljumaily, Raid, Bedard, Philippe L., Sachdev, Jasgit C., Dunn, Lara, Won, Helen, Bond, John, Jones, Surai, Savage, Heidi M., Scaltriti, Maurizio, Wilson, Timothy R., Wei, Michael C., Hyman, David M.

Volltext

Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models von Moore, Heather M., Savage, Heidi M., O'Brien, Carol, Zhou, Wei, Sokol, Ethan S., Goldberg, Michael E., Metcalfe, Ciara, Friedman, Lori S., Lackner, Mark R., Wilson, Timothy R.

Volltext

Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers von Wilson, Timothy R, Udyavar, Akshata R, Chang, Ching-Wei, Spoerke, Jill M, Aimi, Junko, Savage, Heidi M, Daemen, Anneleen, O'Shaughnessy, Joyce A, Bourgon, Richard, Lackner, Mark R

Volltext

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population von Wilson, Timothy R, Yu, Jianjun, Lu, Xuyang, Spoerke, Jill M, Xiao, Yuanyuan, O’Brien, Carol, Savage, Heidi M, Huw, Ling-Yuh, Zou, Wei, Koeppen, Hartmut, Forrest, William F, Fridlyand, Jane, Fu, Ling, Tam, Rachel, Schleifman, Erica B, Sumiyoshi, Teiko, Molinero, Luciana, Hampton, Garret M, O’Shaughnessy, Joyce A, Lackner, Mark R

Volltext

Abstract 242: Deciphering the role of PTEN as a predictive biomarker to next generation isoform-selective PI3K inhibitors in PIK3CA mutant breast cancer cells von Moore, Heather M., Savage, Heidi M., Lackner, Mark R., Wilson, Timothy R.

Volltext

Abstract 1780: Identifying preclinical predictive biomarkers to taselisib in breast cancer cell lines von Savage, Heidi M., Moore, Heather M., O'Brien, Carol L., Zhou, Wei, Metcalfe, Ciara, Lackner, Mark R., Wilson, Timothy R.

Volltext

Abstract 372: Taselisib enhances the potency of ERBB inhibitors in biomarker-defined subsets of head and neck squamous carcinoma cell lines von Savage, Heidi M., O’Brien, Carol, Moore, Heather, Lackner, Mark R., Yauch, Robert, Settleman, Jeffrey, Wilson, Timothy R.

Volltext

Abstract 2631: Neuregulin-1 expression correlates with sensitivity to the PI3K inhibitor, GDC-0032, outside of PIK3CA mutations in head and neck cancer von Savage, Heidi M., O'Brien, Carol, Yauch, Bob, Settleman, Jeff, Lackner, Mark R., Wilson, Timothy R.

Volltext

Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy von Ignatiadis, Michail, Van den Eynden, Gert, Roberto, Salgado, Fornili, Marco, Bareche, Yacine, Desmedt, Christine, Rothe, Francoise, Maetens, Marion, Venet, David, Holgado, Esther, McNally, Virginia, Kiermaier, Astrid, Savage, Heidi M, Wilson, Timothy R, Cortes, Javier, Schneeweiss, Andreas, Willard-Gallo, Karen, Biganzoli, Elia, Sotiriou, Christos

Volltext

Abstract 5165: The genomic landscape and prognostic implications of somatic alterations in patients (pts) with ER+, HER2-, PIK3CA mutated (mut) advanced breast cancer treated with... von Chen, Jessica W., Dent, Susan, Jacot, William, Cortés, Javier, Krop, Ian E., Stout, Thomas J., Schimmoller, Frauke, Savage, Heidi M., Hutchinson, Katherine E., Wilson, Timothy R.

Volltext

Cellulosic Water and Polyacrylamide Gels Can Delay Wilting and Extend Watering Intervals for Potted Poinsettias Displayed in Interiorscapes von Stamps, Robert H., Savage, Heidi M.

Volltext

Abstract 966: Predictive biomarkers of the AKT inhibitor, GDC-0068, in single agent and combination studies von Savage, Heidi M., Nannini-Pepe, Michelle, Lin, Kui, Atwal, Siminder K., Lackner, Mark R., Punnoose, Elizabeth A.

Volltext

Abstract 303: Developing predictive biomarkers of PI3K/AKT pathway activation von Savage, Heidi M., Mullappally, Berny, Mohan, Sankar, Pandita, Ajay, Shames, David, Lackner, Mark, Punnoose, Elizabeth

Volltext

Preemergence Herbicides for Use in Ornamentals: OH-94/WG058, rev. 3/2012 von Stamps, Robert H., Savage, Heidi M., Rock, Diane K., Norcini, Jeffrey G.

Volltext

Preemergence Herbicides for Use in Ornamentals von Robert H. Stamps, Heidi M. Savage, Diane K. Rock, Jeffrey G. Norcini

Volltext

Preemergence Herbicides for Use in Ornamentals von Robert H. Stamps, Heidi M. Savage, Diane K. Rock, Jeffrey G. Norcini

Volltext